These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 20726808

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Nodular regenerative hyperplasia as a complication of thiopurine treatment in a patient with inflammatory bowel disease].
    Cohen-Ezra O, Avni Y, Morgenstern S, Ben-Ari Z.
    Harefuah; 2012 Dec; 151(12):675-8, 721. PubMed ID: 23330258
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
    Musumba CO.
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1025-37. PubMed ID: 24099468
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM.
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [Abstract] [Full Text] [Related]

  • 11. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy.
    Seiderer J, Zech CJ, Diebold J, Schoenberg SO, Brand S, Tillack C, Göke B, Ochsenkühn T.
    Eur J Gastroenterol Hepatol; 2006 May; 18(5):553-5. PubMed ID: 16607155
    [Abstract] [Full Text] [Related]

  • 12. [Azathioprine-induced hepatotoxicity in a patient with Crohn's disease].
    Ruiz-Clavijo D, Arín A, Vila JJ, Albéniz E, Picazo R, Casi M.
    An Sist Sanit Navar; 2013 Sep 06; 36(2):353-6. PubMed ID: 24008542
    [Abstract] [Full Text] [Related]

  • 13. Myelotoxicity and hepatotoxicity during azathioprine therapy.
    de Boer NK, Mulder CJ, van Bodegraven AA.
    Neth J Med; 2005 Dec 06; 63(11):444-6. PubMed ID: 16397313
    [Abstract] [Full Text] [Related]

  • 14. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine.
    Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, Cadiot G, Bouhnik Y, De Vos M, Boureille A, Duclos B, Seksik P, Mary JY, Colombel JF.
    Gut; 2007 Oct 06; 56(10):1404-9. PubMed ID: 17504943
    [Abstract] [Full Text] [Related]

  • 15. Azathioprine induced serious portal hypertension: a case series of three IBD patients and review of the literature.
    Dooremont D, Decaestecker J, De Wulf D, Ghillebert G, Van Vlierberghe H, Van Dorpe J, Baert F.
    Acta Gastroenterol Belg; 2013 Sep 06; 76(3):342-6. PubMed ID: 24261031
    [Abstract] [Full Text] [Related]

  • 16. Leukopenia due to parvovirus B19 in a Crohn's disease patient using azathioprine.
    van Asseldonk DP, Kanis BM, de Boer NK, van Bodegraven AA.
    Digestion; 2009 Sep 06; 79(4):211-4. PubMed ID: 19390192
    [Abstract] [Full Text] [Related]

  • 17. A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease.
    Thomas C, Monteil-Ganiere C, Mirallié S, Hémont C, Dert C, Léger A, Joyau C, Caldari D, Audrain M.
    J Crohns Colitis; 2018 Jan 24; 12(2):258-261. PubMed ID: 28961694
    [Abstract] [Full Text] [Related]

  • 18. [Thiopurine-induced hyperammonaemic encephalopathy in a patient with Crohn's disease].
    Laish I, Pomeranz I, Kitay-Cohen Y, Konikof F.
    Harefuah; 2012 Dec 24; 151(12):692-5, 720. PubMed ID: 23330262
    [Abstract] [Full Text] [Related]

  • 19. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
    Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B, TOPIC Recruitment Team.
    Gastroenterology; 2015 Oct 24; 149(4):907-17.e7. PubMed ID: 26072396
    [Abstract] [Full Text] [Related]

  • 20. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
    Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM.
    Hepatogastroenterology; 2006 Oct 24; 53(69):399-404. PubMed ID: 16795981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.